Connect your AI

Capricor Therapeutics CAPR Total Revenue

Total Revenue at other companies

PfizerPFE

$14.45B+5.4%

Sarepta Therapeutics, Inc.SRPT

$730.8M-1.9%

PTC TherapeuticsPTCT

$272.55M-76.8%

Celldex TherapeuticsCLDX

$15K-97.8%

VericelVCEL

$68.43M+30.1%

Viridian Therapeutics, Inc.VRDN

$141K+95.8%

Other financials

Income statement

Operating income-$36.8M-47.2%

Net income-$33.9M-39.2%

EPS (diluted)-$0.59-11.3%

Balance sheet

Cash & equivalents$105.4M+266%

Total debt$14.8M+1,083%

Total equity$278.7M+118%

Total assets$326.3M+112%

Cash flow

Operating cash flow-$29.3M-355%

CapEx$5.1M+472%

Free cash flow-$34.4M-369%

Valuation

Market cap$1.71B+303%

Enterprise value$1.62B+308%

Profitability

Operating margin-778.8%-1,038pp

Net margin-736.6%-981pp

FCF margin-563.9%-954pp

Returns & leverage

Return on equity-56.4%-11.3pp

Debt / equity0.1×0.0×

Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Capricor Therapeutics’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Capricor Therapeutics's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Capricor Therapeutics's total revenue?: Capricor Therapeutics (CAPR) reported total revenue of $0 in Q4 2025.
How has Capricor Therapeutics's total revenue changed year-over-year?: Capricor Therapeutics's total revenue decreased by 100.0% year-over-year, from $11.13M to $0.
What is the long-term trend for Capricor Therapeutics's total revenue?: Over 2 years (2023 to 2025), Capricor Therapeutics's total revenue has grown at a -100.0% compound annual growth rate (CAGR), from $25.18M to $0.
What does total revenue mean?: The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.